FDA warns OTC maker over testing program, clinical investigator for failing to adhere to study plan
Regulatory NewsJoanne S. Eglovitch
CDERClinical TrialsComplianceGMPManufacturingOTCPharmaceuticalsQuality Assurance and ControlUnited StatesWarning letters